Stock Track | Hims & Hers Health Plunges 8.43% as Novo Nordisk Threatens Legal Action Over $49 Wegovy Copycat

Stock Track

Feb 06

Hims & Hers Health Inc. (HIMS) experienced a 24-hour plunge of 8.43% during Thursday's trading session and extended hours. The telehealth company's stock faced significant selling pressure following a controversial product launch that drew immediate legal threats from a major pharmaceutical competitor.

The sharp decline was triggered after Novo Nordisk announced plans to pursue legal and regulatory action against Hims & Hers. The Danish drugmaker condemned Hims & Hers' launch of a cheaper, compounded version of its blockbuster Wegovy weight-loss pill at an introductory price of $49 per month as "illegal mass compounding" that poses significant risks to patient safety.

Adding to the market uncertainty, FDA Commissioner Marty Makary stated that the agency would take swift action against companies marketing "illegal copycat drugs," creating concerns about the regulatory viability of Hims & Hers' new offering. This combination of competitive legal threats and regulatory scrutiny prompted investors to sell shares, driving the substantial price decline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1143340533"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1143340533\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1143340533?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-06 09:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143340533","market":"nz","top_or_hot":-1,"title":"Stock Track | Hims & Hers Health Plunges 8.43% as Novo Nordisk Threatens Legal Action Over $49 Wegovy Copycat","media":"Stock Track","content":"<p>Hims & Hers Health Inc. (HIMS) experienced a 24-hour plunge of 8.43% during Thursday's trading session and extended hours. The telehealth company's stock faced significant selling pressure following a controversial product launch that drew immediate legal threats from a major pharmaceutical competitor.</p><p>The sharp decline was triggered after Novo Nordisk announced plans to pursue legal and regulatory action against Hims & Hers. The Danish drugmaker condemned Hims & Hers' launch of a cheaper, compounded version of its blockbuster Wegovy weight-loss pill at an introductory price of $49 per month as \"illegal mass compounding\" that poses significant risks to patient safety.</p><p>Adding to the market uncertainty, FDA Commissioner Marty Makary stated that the agency would take swift action against companies marketing \"illegal copycat drugs,\" creating concerns about the regulatory viability of Hims & Hers' new offering. This combination of competitive legal threats and regulatory scrutiny prompted investors to sell shares, driving the substantial price decline.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Health Plunges 8.43% as Novo Nordisk Threatens Legal Action Over $49 Wegovy Copycat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Health Plunges 8.43% as Novo Nordisk Threatens Legal Action Over $49 Wegovy Copycat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-06 09:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hims & Hers Health Inc. (HIMS) experienced a 24-hour plunge of 8.43% during Thursday's trading session and extended hours. The telehealth company's stock faced significant selling pressure following a controversial product launch that drew immediate legal threats from a major pharmaceutical competitor.</p><p>The sharp decline was triggered after Novo Nordisk announced plans to pursue legal and regulatory action against Hims & Hers. The Danish drugmaker condemned Hims & Hers' launch of a cheaper, compounded version of its blockbuster Wegovy weight-loss pill at an introductory price of $49 per month as \"illegal mass compounding\" that poses significant risks to patient safety.</p><p>Adding to the market uncertainty, FDA Commissioner Marty Makary stated that the agency would take swift action against companies marketing \"illegal copycat drugs,\" creating concerns about the regulatory viability of Hims & Hers' new offering. This combination of competitive legal threats and regulatory scrutiny prompted investors to sell shares, driving the substantial price decline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1143340533","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143340533","pubTimestamp":1770339818,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Hims & Hers Health Inc. (HIMS) experienced a 24-hour plunge of 8.43% during Thursday's trading session and extended hours. The telehealth company's stock faced significant selling pressure following...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"股票追踪|Hims&Hers Health暴跌8.43%，诺和诺德威胁对49美元的Wegovy山寨产品采取法律行动","themeId":"f0fce81d99e7c4115b5691df849cabad","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Hims & Hers Health Inc. (HIMS) experienced a 24-hour plunge of 8.43% during Thursday's trading session and extended hours. The telehealth company's stock faced significant selling pressure following a controversial product launch that drew immediate legal threats from a major pharmaceutical competitor.The sharp decline was triggered after Novo Nordisk announced plans to pursue legal and regulatory action against Hims & Hers. The Danish drugmaker condemned Hims & Hers' launch of a cheaper, compounded version of its blockbuster Wegovy weight-loss pill at an introductory price of $49 per month as \"illegal mass compounding\" that poses significant risks to patient safety.Adding to the market uncertainty, FDA Commissioner Marty Makary stated that the agency would take swift action against companies marketing \"illegal copycat drugs,\" creating concerns about the regulatory viability of Hims & Hers' new offering. This combination of competitive legal threats and regulatory scrutiny prompted investors to sell shares, driving the substantial price decline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}